As a co-stimulatory receptor that mediates T cell adhesion and execution of cytotoxicity (92), CD226 competes with immune checkpoints like TIGIT for the same ligands expressed by cancer cells to execute the anti-tumor effects (93–95). This evidence concerns the gene TIGIT and neoplasm.